bioAffinity Technologies (BIAF) Share-based Compensation (2021 - 2026)

bioAffinity Technologies has disclosed Share-based Compensation across 6 years of filings, most recently posting $14340.0 for Q1 2026.

• In Q1 2026, Share-based Compensation fell 95.61% year-over-year to $14340.0; the TTM figure through Mar 2026 stood at $359198.0 (down 65.25% YoY), while the FY2025 annual figure was $671474.0, down 32.15% from the prior year.
• Share-based Compensation declined to $14340.0 in Q1 2026, from $66119.0 in the prior quarter.
• Over the last five years, Share-based Compensation for BIAF reached as high as $326616.0 in Q1 2025 and fell as low as $14340.0 in Q1 2026.
• The 5-year median for Share-based Compensation is $157613.0 (2023), against an average of $151277.0.
• Annual changes were most pronounced in 2023 — Share-based Compensation surged 538.01% — and 2026, when it plunged 95.61%.
• A 5-year view of Share-based Compensation shows it stood at $36847.0 in 2022, then surged by 536.44% to $234510.0 in 2023, then declined by 0.18% to $234087.0 in 2024, then plunged by 71.75% to $66119.0 in 2025, then tumbled by 78.31% to $14340.0 in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $14340.0, $66119.0, and $67132.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.